A previous study on the peripheral T cell profiles of NSCLC patients before and early after anti-PD-1 therapy indicated that patients with severe irAEs (defined as grade 3 and higher) exhibited significantly lower fold increases in the frequency of effector Treg cells27. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.